AGN 195.12 Allergan Inc $AGN Hit a 52 week high of
Post# of 58
Posted On: 11/05/2014 5:48:27 AM
AGN 195.12 Allergan Inc $AGN Hit a 52 week high of 196.54 Closing the day 11/04/14 at 195.12 +1.98 +1.03% With a day low of 189.47 and a total volume of 3,485,500.
AGN Recent Posts: http://investorshangout.com/Allergan-AGN-50031/
AGN Allergan Inc Recent Headline News
These 5 Drugmakers' Earnings Excelled This Quarter
at Investor's Business Daily - Tue Nov 04, 7:14PM CST
Big pharma firms such as Alexion Pharmaceuticals and Biogen Idec continue to outperform the market as they develop and market new treatments to treat long-time targets such as Alzheimer's as well as rare illnesses. Today's Screen Of The Day is Big...
AGN: 195.12 (+1.98), BIIB: 322.06 (+0.81), VRX: 133.61 (+0.76), ACT: 245.32 (-2.18), JAZZ: 168.48 (-1.85), ALXN: 191.30 (+0.26), CELG: 105.75 (-1.66)
Top Funds Buy Ulta Beauty, Alexion, Avago
at Investor's Business Daily - Tue Nov 04, 5:52PM CST
Managers of leading mutual funds in recent months have continued to stock up on large medical stocks, such as Illumina (ILMN), Alexion Pharmaceuticals (ALXN), Celgene (CELG), Jazz Pharmaceuticals (JAZZ),Allergan (AGN) and Centene (CNC). The...
AMBA: 45.48 (-2.08), MNST: 100.04 (-1.19), SWKS: 60.42 (+0.19), GMCR: 152.11 (+0.21), ILMN: 191.41 (-2.92), WSM: 64.33 (-0.63), NXPI: 69.67 (+0.42), CELG: 105.75 (-1.66), HAIN: 106.79 (-1.55), AGN: 195.12 (+1.98), CNC: 92.04 (+0.47), V: 242.97 (+1.43), CALM: 43.15 (-0.17), JAZZ: 168.48 (-1.85), ALXN: 191.30 (+0.26), LOW: 57.26 (-0.19), ULTA: 120.11 (+0.20), MA: 83.99 (-0.14), AVGO: 85.36 (-0.98), PETM: 70.70 (-1.00)
Allergan takeover closer?
at Investor's Business Daily - Tue Nov 04, 5:52PM CST
Valeant's (VRX) hostile takeover of the Botox maker may be closer now that a federal judge denied Allergan's (AGN) request to stop activist investor Bill Ackman and his Pershing Square Capital Management from voting against board members opposed to...
AGN: 195.12 (+1.98), VRX: 133.61 (+0.76)
Bristol-Myers Signs Option Deal to Acquire Galecto Biotech - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 04, 4:30PM CST
Bristol-Myers Squibb Company (BMY) and Denmark-based Galecto Biotech AB announced that both companies have entered into an agreement whereby Bristol-Myers Squibb will have an exclusive option to acquire Galecto Biotech AB.
AGN: 195.12 (+1.98), ABBV: 62.66 (-0.59), TEVA: 57.99 (+0.19), BMY: 57.84 (+0.04)
After Yesterday's Rally of 1.03% Shares Could Potentially Pullback
Comtex SmarTrend(R) - Tue Nov 04, 3:52PM CST
Allergan (AMEX:AGN) traded in a range yesterday that spanned from a low of $189.47 to a high of $196.54. Yesterday, the shares gained 1.0%, which took the trading range above the 3-day high of $193.63 on volume of 3.4 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
AGN: 195.12 (+1.98)
Allergan Comments on California Federal Court Ruling in Insider Trading Lawsuit against Valeant & Pershing Square
Business Wire - Tue Nov 04, 12:56PM CST
--Court Orders Valeant and Pershing Square to Correct Disclosures; Parties Enjoined from Voting Until Corrective Disclosures are Made
AGN: 195.12 (+1.98)
Video: Top 3 Earnings Reports To Watch Wednesday
at Investor's Business Daily - Tue Nov 04, 12:45PM CST
Several highly rated tech companies and drugmakers are set to report earnings on Wednesday. Here's a look at what analysts expect. Actavis (ACT) reports its results before the open. The specialty-drug giant is projected to earn $3.10 a share, a 48%...
AGN: 195.12 (+1.98), TSLA: 238.93 (-3.66), VRX: 133.61 (+0.76), ACT: 245.32 (-2.18), ATHM: 50.19 (-0.40)
Valeant And Pershing Square May Vote At Special Meeting
CNW Group - Tue Nov 04, 12:27PM CST
Today, the United States District Court for the Central District of California held that Pershing Square Capital Management, L.P., Valeant Pharmaceuticals International, Inc. (NYSE: VRX) (TSX: VRX) and related parties may vote shares of Allergan, Inc. (NYSE: AGN) or proxies at the upcoming December 18 stockholder meeting. Allergan had sought to disenfranchise its largest shareholder, PS Fund 1, along with other shareholders solicited by PS Fund 1, by seeking an injunction to prevent them from voting at Allergan's December 18 special meeting. Today's ruling by Judge David O. Carter means that all Allergan shareholders, including PS Fund 1, will be permitted to have their voices heard by voting at the special meeting.
AGN: 195.12 (+1.98), VRX: 133.61 (+0.76), VRX.TO: 152.41 (+1.51)
Salix, Skyworks Lead 6 IBD50 EarningsReports On Tap
at Investor's Business Daily - Tue Nov 04, 7:02AM CST
Earnings season continues to barrel forward, and investors are anticipating results from several top drugmakers this upcoming week. This week's IBD 50, a roundup of top-rated growth stocks with solid fundamentals, boasts six companies reporting...
DRTX: 23.98 (-0.05), AGN: 195.12 (+1.98), ACT: 245.32 (-2.18), SWKS: 60.42 (+0.19), AKRX: 42.64 (-1.18), JAZZ: 168.48 (-1.85), SLXP: 140.45 (-2.74), AAPL: 108.60 (-0.80), ATHM: 50.19 (-0.40)
One Reason Allergan (AGN) Stock Is Higher Today
at The Street - Mon Nov 03, 1:16PM CST
The Botox maker, fighting off an acquisition by Valeant Pharmaceuticals (VRX), said today that it had been approached by another party about a possible transaction.
AGN: 195.12 (+1.98)
Novo Nordisk's Earnings Rise in Q3, 2014 Outlook Narrowed - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Nov 03, 10:10AM CST
Novo Nordisk's (NVO) reported third-quarter 2014 earnings of 44 cents per American Depository Receipt (ADR), higher than the year-ago earnings of 42 cents.
AGN: 195.12 (+1.98), NVO: 44.18 (+0.07), GILD: 109.72 (-0.26), ABBV: 62.66 (-0.59)
Quarterly Financial & Operational Results Release and Dividends - Research Reports on AFLAC, BlackRock, Allergan, Cabot and Cheniere Energy
PR Newswire - Mon Nov 03, 7:40AM CST
Today, Analysts Review released its research reports regarding AFLAC Inc. (NYSE: AFL), BlackRock, Inc (NYSE: BLK), Allergan Inc. (NYSE: AGN), Cabot Oil & Gas Corporation (NYSE: COG) and Cheniere Energy, Inc. (NYSEMKT: LNG). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/7630-100free.
AGN: 195.12 (+1.98), COG: 30.73 (-0.08), BLK: 341.53 (+2.73), LNG: 70.84 (-3.52), AFL: 59.48 (+0.15)
Bristol-Myers Squibb Up on Positive Opdivo Phase II Study - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Oct 31, 3:46PM CDT
Bristol-Myers Squibb Company announced encouraging data from the phase II CheckMate - 063 study on immuno-oncology drug Opdivo.
MNK: 94.09 (+0.66), AGN: 195.12 (+1.98), ACT: 245.32 (-2.18), BMY: 57.84 (+0.04)
Cramer on the Stock Market: Find the Best of Best-of-Breed Stocks
at The Street - Fri Oct 31, 9:54AM CDT
Remember these franchises and who captains them.
AGN: 195.12 (+1.98), MMM: 155.05 (+1.75), CMG: 647.68 (+9.15), BMY: 57.84 (+0.04)
AbbVie Q3 Earnings Top on Humira Sales, Boosts Outlook - Analyst Blog
Arpita Dutt - Zacks Investment Research - Fri Oct 31, 9:33AM CDT
AbbVie (ABBV) raised it outlook for 2014 - the new guidance surpassed expectations.
AGN: 195.12 (+1.98), SHPG: 195.62 (-0.87), ABBV: 62.66 (-0.59), BMY: 57.84 (+0.04)
Global Hyaluronic Acid (HA) (Dermal Fillers, Osteoarthritis, Ophthalmic & VUR) Market Outlook, 2018
M2 - Fri Oct 31, 6:40AM CDT
Research and Markets (http://www.researchandmarkets.com/research/cg7ml7/global_hyaluronic) has announced the addition of the "Global Hyaluronic Acid (HA) Market 2014-2018" report to their offering. The Global HA Market will grow at a CAGR of 9.14% over the period 2013-2018 Hyaluronic acid (HA) or glass acid is a naturally occurring non-sulfated glycosaminoglycan. It is present in the human body in the joints, eye cavity, and internal defense systems. It functions as a nutrient carrier, along with helping the tissues in retaining water. It is an integral part of the extracellular matrix and is found in the coverings around chondrocytes. HA is produced commercially by various processes, including extraction from animal tissues, bacterial production, and in-vitro production. Its major medical applications are viscosupplementation for osteoarthritis, ophthalmic, VUR, and dermal fillers. HA is commercially available in the form of single-injection cycle HA products, three-injection cycle HA products, and five-injection cycle HA products. The shift in consumer preference for premium priced single-injection cycle HA products over low-priced five-injection cycle HA products owing to the shorter treatment regimen is the major positive trend being witnessed in this market. The shorter regimens are more convenient as patients want to reduce the number of steps in the treatment owing to the side effects and pain felt after each injection. According to the report, the growth in the geriatric population globally is one of the major drivers in the market. HA is used extensively in the Medical sector for treating osteoarthritic patients through viscosupplementation. As osteoarthritis is caused by the deterioration of body's ability to repair its cartilage with increasing age, the Global HA market is expected to experience strong growth as a result of the increasing geriatric population. Further, the report states that the threat of substitution by utilizing an alternative method for the treatment of osteoarthritis is the major obstacle hindering the growth of this market. There has been an increase in the number of substitutes for HA viscosupplementation for the treatment of osteoarthritis in recent years including cyclooxygenase-2 inhibitors and joint arthroplasty. The development and popularity of new procedures is making it difficult for manufacturers in the market to maintain their market share. The Global HA market can be divided on the basis of application into the following segments: - Dermal Fillers - Osteoarthritis - Ophthalmic - VUR Key Vendors - Allergan - Ferring Pharmaceuticals - Fidia Farmaceutici - Sanofi - Seikagaku For more information visit http://www.researchandmarkets.com/research/cg...hyaluronic
AGN: 195.12 (+1.98)
Eli Lilly/Boehringer Ingelheim Restructure Diabetes Deal - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Oct 30, 5:05PM CDT
Eli Lilly (LLY) and partner Boehringer Ingelheim amended the operational and financial structure of their diabetes collaboration in certain countries.
AGN: 195.12 (+1.98), ABBV: 62.66 (-0.59), LLY: 67.17 (+0.63), BMY: 57.84 (+0.04)
Sanofi Beats on Q3 Earnings but Lantus Outlook Disappoints - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Oct 30, 1:45PM CDT
Sanofi reported third-quarter 2014 business earnings of 97 cents per ADS, 3 cents above the Zacks Consensus Estimate.
AGN: 195.12 (+1.98), NVO: 44.18 (+0.07), ABBV: 62.66 (-0.59), SNY: 45.49 (-0.29)
AGN Recent Posts: http://investorshangout.com/Allergan-AGN-50031/
AGN Allergan Inc Recent Headline News
These 5 Drugmakers' Earnings Excelled This Quarter
at Investor's Business Daily - Tue Nov 04, 7:14PM CST
Big pharma firms such as Alexion Pharmaceuticals and Biogen Idec continue to outperform the market as they develop and market new treatments to treat long-time targets such as Alzheimer's as well as rare illnesses. Today's Screen Of The Day is Big...
AGN: 195.12 (+1.98), BIIB: 322.06 (+0.81), VRX: 133.61 (+0.76), ACT: 245.32 (-2.18), JAZZ: 168.48 (-1.85), ALXN: 191.30 (+0.26), CELG: 105.75 (-1.66)
Top Funds Buy Ulta Beauty, Alexion, Avago
at Investor's Business Daily - Tue Nov 04, 5:52PM CST
Managers of leading mutual funds in recent months have continued to stock up on large medical stocks, such as Illumina (ILMN), Alexion Pharmaceuticals (ALXN), Celgene (CELG), Jazz Pharmaceuticals (JAZZ),Allergan (AGN) and Centene (CNC). The...
AMBA: 45.48 (-2.08), MNST: 100.04 (-1.19), SWKS: 60.42 (+0.19), GMCR: 152.11 (+0.21), ILMN: 191.41 (-2.92), WSM: 64.33 (-0.63), NXPI: 69.67 (+0.42), CELG: 105.75 (-1.66), HAIN: 106.79 (-1.55), AGN: 195.12 (+1.98), CNC: 92.04 (+0.47), V: 242.97 (+1.43), CALM: 43.15 (-0.17), JAZZ: 168.48 (-1.85), ALXN: 191.30 (+0.26), LOW: 57.26 (-0.19), ULTA: 120.11 (+0.20), MA: 83.99 (-0.14), AVGO: 85.36 (-0.98), PETM: 70.70 (-1.00)
Allergan takeover closer?
at Investor's Business Daily - Tue Nov 04, 5:52PM CST
Valeant's (VRX) hostile takeover of the Botox maker may be closer now that a federal judge denied Allergan's (AGN) request to stop activist investor Bill Ackman and his Pershing Square Capital Management from voting against board members opposed to...
AGN: 195.12 (+1.98), VRX: 133.61 (+0.76)
Bristol-Myers Signs Option Deal to Acquire Galecto Biotech - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 04, 4:30PM CST
Bristol-Myers Squibb Company (BMY) and Denmark-based Galecto Biotech AB announced that both companies have entered into an agreement whereby Bristol-Myers Squibb will have an exclusive option to acquire Galecto Biotech AB.
AGN: 195.12 (+1.98), ABBV: 62.66 (-0.59), TEVA: 57.99 (+0.19), BMY: 57.84 (+0.04)
After Yesterday's Rally of 1.03% Shares Could Potentially Pullback
Comtex SmarTrend(R) - Tue Nov 04, 3:52PM CST
Allergan (AMEX:AGN) traded in a range yesterday that spanned from a low of $189.47 to a high of $196.54. Yesterday, the shares gained 1.0%, which took the trading range above the 3-day high of $193.63 on volume of 3.4 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
AGN: 195.12 (+1.98)
Allergan Comments on California Federal Court Ruling in Insider Trading Lawsuit against Valeant & Pershing Square
Business Wire - Tue Nov 04, 12:56PM CST
--Court Orders Valeant and Pershing Square to Correct Disclosures; Parties Enjoined from Voting Until Corrective Disclosures are Made
AGN: 195.12 (+1.98)
Video: Top 3 Earnings Reports To Watch Wednesday
at Investor's Business Daily - Tue Nov 04, 12:45PM CST
Several highly rated tech companies and drugmakers are set to report earnings on Wednesday. Here's a look at what analysts expect. Actavis (ACT) reports its results before the open. The specialty-drug giant is projected to earn $3.10 a share, a 48%...
AGN: 195.12 (+1.98), TSLA: 238.93 (-3.66), VRX: 133.61 (+0.76), ACT: 245.32 (-2.18), ATHM: 50.19 (-0.40)
Valeant And Pershing Square May Vote At Special Meeting
CNW Group - Tue Nov 04, 12:27PM CST
Today, the United States District Court for the Central District of California held that Pershing Square Capital Management, L.P., Valeant Pharmaceuticals International, Inc. (NYSE: VRX) (TSX: VRX) and related parties may vote shares of Allergan, Inc. (NYSE: AGN) or proxies at the upcoming December 18 stockholder meeting. Allergan had sought to disenfranchise its largest shareholder, PS Fund 1, along with other shareholders solicited by PS Fund 1, by seeking an injunction to prevent them from voting at Allergan's December 18 special meeting. Today's ruling by Judge David O. Carter means that all Allergan shareholders, including PS Fund 1, will be permitted to have their voices heard by voting at the special meeting.
AGN: 195.12 (+1.98), VRX: 133.61 (+0.76), VRX.TO: 152.41 (+1.51)
Salix, Skyworks Lead 6 IBD50 EarningsReports On Tap
at Investor's Business Daily - Tue Nov 04, 7:02AM CST
Earnings season continues to barrel forward, and investors are anticipating results from several top drugmakers this upcoming week. This week's IBD 50, a roundup of top-rated growth stocks with solid fundamentals, boasts six companies reporting...
DRTX: 23.98 (-0.05), AGN: 195.12 (+1.98), ACT: 245.32 (-2.18), SWKS: 60.42 (+0.19), AKRX: 42.64 (-1.18), JAZZ: 168.48 (-1.85), SLXP: 140.45 (-2.74), AAPL: 108.60 (-0.80), ATHM: 50.19 (-0.40)
One Reason Allergan (AGN) Stock Is Higher Today
at The Street - Mon Nov 03, 1:16PM CST
The Botox maker, fighting off an acquisition by Valeant Pharmaceuticals (VRX), said today that it had been approached by another party about a possible transaction.
AGN: 195.12 (+1.98)
Novo Nordisk's Earnings Rise in Q3, 2014 Outlook Narrowed - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Nov 03, 10:10AM CST
Novo Nordisk's (NVO) reported third-quarter 2014 earnings of 44 cents per American Depository Receipt (ADR), higher than the year-ago earnings of 42 cents.
AGN: 195.12 (+1.98), NVO: 44.18 (+0.07), GILD: 109.72 (-0.26), ABBV: 62.66 (-0.59)
Quarterly Financial & Operational Results Release and Dividends - Research Reports on AFLAC, BlackRock, Allergan, Cabot and Cheniere Energy
PR Newswire - Mon Nov 03, 7:40AM CST
Today, Analysts Review released its research reports regarding AFLAC Inc. (NYSE: AFL), BlackRock, Inc (NYSE: BLK), Allergan Inc. (NYSE: AGN), Cabot Oil & Gas Corporation (NYSE: COG) and Cheniere Energy, Inc. (NYSEMKT: LNG). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/7630-100free.
AGN: 195.12 (+1.98), COG: 30.73 (-0.08), BLK: 341.53 (+2.73), LNG: 70.84 (-3.52), AFL: 59.48 (+0.15)
Bristol-Myers Squibb Up on Positive Opdivo Phase II Study - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Oct 31, 3:46PM CDT
Bristol-Myers Squibb Company announced encouraging data from the phase II CheckMate - 063 study on immuno-oncology drug Opdivo.
MNK: 94.09 (+0.66), AGN: 195.12 (+1.98), ACT: 245.32 (-2.18), BMY: 57.84 (+0.04)
Cramer on the Stock Market: Find the Best of Best-of-Breed Stocks
at The Street - Fri Oct 31, 9:54AM CDT
Remember these franchises and who captains them.
AGN: 195.12 (+1.98), MMM: 155.05 (+1.75), CMG: 647.68 (+9.15), BMY: 57.84 (+0.04)
AbbVie Q3 Earnings Top on Humira Sales, Boosts Outlook - Analyst Blog
Arpita Dutt - Zacks Investment Research - Fri Oct 31, 9:33AM CDT
AbbVie (ABBV) raised it outlook for 2014 - the new guidance surpassed expectations.
AGN: 195.12 (+1.98), SHPG: 195.62 (-0.87), ABBV: 62.66 (-0.59), BMY: 57.84 (+0.04)
Global Hyaluronic Acid (HA) (Dermal Fillers, Osteoarthritis, Ophthalmic & VUR) Market Outlook, 2018
M2 - Fri Oct 31, 6:40AM CDT
Research and Markets (http://www.researchandmarkets.com/research/cg7ml7/global_hyaluronic) has announced the addition of the "Global Hyaluronic Acid (HA) Market 2014-2018" report to their offering. The Global HA Market will grow at a CAGR of 9.14% over the period 2013-2018 Hyaluronic acid (HA) or glass acid is a naturally occurring non-sulfated glycosaminoglycan. It is present in the human body in the joints, eye cavity, and internal defense systems. It functions as a nutrient carrier, along with helping the tissues in retaining water. It is an integral part of the extracellular matrix and is found in the coverings around chondrocytes. HA is produced commercially by various processes, including extraction from animal tissues, bacterial production, and in-vitro production. Its major medical applications are viscosupplementation for osteoarthritis, ophthalmic, VUR, and dermal fillers. HA is commercially available in the form of single-injection cycle HA products, three-injection cycle HA products, and five-injection cycle HA products. The shift in consumer preference for premium priced single-injection cycle HA products over low-priced five-injection cycle HA products owing to the shorter treatment regimen is the major positive trend being witnessed in this market. The shorter regimens are more convenient as patients want to reduce the number of steps in the treatment owing to the side effects and pain felt after each injection. According to the report, the growth in the geriatric population globally is one of the major drivers in the market. HA is used extensively in the Medical sector for treating osteoarthritic patients through viscosupplementation. As osteoarthritis is caused by the deterioration of body's ability to repair its cartilage with increasing age, the Global HA market is expected to experience strong growth as a result of the increasing geriatric population. Further, the report states that the threat of substitution by utilizing an alternative method for the treatment of osteoarthritis is the major obstacle hindering the growth of this market. There has been an increase in the number of substitutes for HA viscosupplementation for the treatment of osteoarthritis in recent years including cyclooxygenase-2 inhibitors and joint arthroplasty. The development and popularity of new procedures is making it difficult for manufacturers in the market to maintain their market share. The Global HA market can be divided on the basis of application into the following segments: - Dermal Fillers - Osteoarthritis - Ophthalmic - VUR Key Vendors - Allergan - Ferring Pharmaceuticals - Fidia Farmaceutici - Sanofi - Seikagaku For more information visit http://www.researchandmarkets.com/research/cg...hyaluronic
AGN: 195.12 (+1.98)
Eli Lilly/Boehringer Ingelheim Restructure Diabetes Deal - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Oct 30, 5:05PM CDT
Eli Lilly (LLY) and partner Boehringer Ingelheim amended the operational and financial structure of their diabetes collaboration in certain countries.
AGN: 195.12 (+1.98), ABBV: 62.66 (-0.59), LLY: 67.17 (+0.63), BMY: 57.84 (+0.04)
Sanofi Beats on Q3 Earnings but Lantus Outlook Disappoints - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Oct 30, 1:45PM CDT
Sanofi reported third-quarter 2014 business earnings of 97 cents per ADS, 3 cents above the Zacks Consensus Estimate.
AGN: 195.12 (+1.98), NVO: 44.18 (+0.07), ABBV: 62.66 (-0.59), SNY: 45.49 (-0.29)
(0)
(0)Allergan Inc. (AGN) Stock Research Links
Scroll down for more posts ▼